English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Infliximab (IFX) is currently registered for use in Crohn’s disease (CD) in children over 7 years of age. So far, there are not enough satisfactory data on maintenance therapy with IFX in children with CD from Eastern and Medium Europe. Aim: Therefore, we carried out this trial in order to assess the benefit of maintenance therapy with infliximab in paediatric patients with active Crohn’s disease who responded to induction therapy with 3 doses of infliximab. Material and methods: The study group consisted of 32 CD children aged 14.8; 12.9; 16.3 (median; Q1; Q3) with active Crohn’s disease (Crohn’s Disease Activity Index (PCDAI) > 30) who have finished induction therapy with infliximab (5 mg/ kg) in three repeated infusions. After assessment of remission at week 10, patients were assigned repeat 5 mg/kg infliximab every 8 weeks thereafter until week 46; weeks 14, 22, 30, 38, 46. The clinical activity of the disease by means of the PCDAI and endoscopic activity by means of the SES-CD together with laboratory tests were assessed at week 10 and 50. Adverse events monitoring had been conducted. Descriptive data analysis was performed with Statistica (StatSoft Polska) ver. 5.11 software package. A non-parametric statistical hypothesis test, Mann-Whitney U test, was used to assess whether two independent samples of observations had equally large values. Value of p < 0.05 was regarded as significant. Streszczenie

przegląd gastroenterologiczny

Maintenance therapy with infliximab for paediatric Crohn’s disease: impact on clinical remission and mucosal healing in Polish paediatric patients with severe Crohn’s disease